The eGFR Dip on a GLP-1: Kidney Damage or Normal?

If your eGFR ticked down (or creatinine ticked up) in the first weeks of a GLP-1, that is usually not kidney damage — it is most often a benign, reversible hemodynamic dip, the same pattern seen when starting other kidney-protective drugs (ACE inhibitors, SGLT2 inhibitors). The big-picture evidence is reassuring and then some: in the landmark FLOW trial, once-weekly semaglutide reduced major kidney-disease events by 24% in people with type 2 diabetes and chronic kidney disease (Perkovic 2024 ^[1]), with benefit on top of SGLT2 inhibitors (Mann 2024 ^[2]). The drug is now changing kidney-disease care. This article explains the early dip, when it's normal, and the rare cases that aren't.

The honest summary

• A small early eGFR dip is common and usually benign. It typically reflects a hemodynamic adjustment in how the kidney filters — not injury — and it tends to stabilize.
• GLP-1 therapy protects the kidney long-term. FLOW (Perkovic 2024^[1]) showed semaglutide cut the composite of kidney failure, ≥50% eGFR loss, and kidney/cardiovascular death by 24% in type 2 diabetes with CKD.
• The benefit stacks with SGLT2 inhibitors. Mann 2024^[2] found the FLOW kidney benefit held whether or not patients were also on an SGLT2 inhibitor — the two work through complementary mechanisms.
• The dehydration scenario is the real risk. The one way a GLP-1 can genuinely hurt the kidney is indirectly: severe nausea/vomiting/diarrhea causing dehydration and acute kidney injury (AKI). That is a fluid problem, not a direct kidney toxicity.
• Context matters. FLOW enrolled people with reduced kidney function (eGFR 50–75) and ran on top of standard care (Rossing 2023^[3]) — this is a studied population, not a contraindication.

Why eGFR can dip early — and why that's usually fine

eGFR (estimated glomerular filtration rate) is calculated from your creatinine and estimates how fast your kidneys filter. A modest, early decline when starting certain drugs is a recognized, generally benign phenomenon: the drug changes the pressure dynamics inside the kidney's filtering units (the glomeruli), which slightly lowers the measured filtration rate at first. This is exactly what happens — and is considered protective — when starting ACE inhibitors, ARBs, and SGLT2 inhibitors: a small initial “dip” followed by a slower long-term decline (a better eGFR slope) than without the drug. The same hemodynamic logic applies with GLP-1 therapy in many patients. Clinicians expect a small early change and watch the trajectory, not a single value.

Crucially, a falling eGFR from this mechanism is not the kidney being injured — it is the kidney being relieved of the chronic hyperfiltration stress that drives diabetic kidney disease. That is why the long-term outcome is better, not worse, which is exactly what FLOW demonstrated.

FLOW: from a lab nuance to a kidney-protective drug

FLOW (Perkovic 2024^[1], New England Journal of Medicine) randomized people with type 2 diabetes and chronic kidney disease (baseline eGFR 50–75 ml/min/1.73 m², with albuminuria) to once-weekly semaglutide or placebo. The primary outcome was a composite of major kidney-disease events: onset of kidney failure (dialysis, transplant, or eGFR <15), at least a 50% reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. The risk of a primary-outcome event was 24% lower with semaglutide. Mann 2024^[2] (Nature Medicine) showed the kidney benefit was consistent whether or not participants were also taking an SGLT2 inhibitor — meaning a GLP-1 adds protection on top of the other major kidney-protective class. The trial's rationale and design are detailed in Rossing 2023^[3].

When a kidney change IS a concern

The genuine GLP-1 kidney risk is indirect and tied to volume: if GI side effects (severe nausea, vomiting, or diarrhea, especially during dose escalation) leave you dehydrated, that can cause acute kidney injury — a real but preventable problem. Warning signs include markedly reduced urination, dizziness/lightheadedness, and a sharp creatinine rise rather than the small early dip. The defenses are simple: stay hydrated, don't push through severe GI symptoms, and be cautious with other kidney-stressing drugs (NSAIDs, and sometimes ACE inhibitors/ARBs and diuretics — the “sick-day” hold) when you're vomiting. A large or progressive eGFR fall, or any of those symptoms, should prompt a call to your clinician rather than reassurance.

What to do with your numbers

• Small early eGFR dip / mild creatinine rise, feeling well: usually the expected hemodynamic adjustment — your clinician monitors the trend.
• On an SGLT2 inhibitor too? Both can cause a small initial dip and both protect the kidney long-term; the combination is studied and beneficial (Mann 2024^[2]).
• Sharp creatinine rise, low urine output, dizziness, or severe GI symptoms: possible dehydration/AKI — contact your clinician promptly and rehydrate.
• Advanced CKD or on dialysis: GLP-1 use is increasingly studied (FLOW enrolled eGFR down to 50), but advanced kidney disease needs individualized, specialist-guided decisions.

Bottom line

A small early eGFR dip or creatinine bump on a GLP-1 is usually a benign hemodynamic effect — the same protective pattern seen with ACE inhibitors and SGLT2 inhibitors — and the long-term kidney outcome is better: FLOW cut major kidney-disease events by 24%^[1], with benefit additive to SGLT2 inhibitors^[2]. The real risk to watch is dehydration-driven acute kidney injury from severe GI side effects, not the early dip. Track the trend with your clinician, and act fast on dehydration.

Related: The benign early creatinine dip described here is not kidney damage. For the "does Ozempic harm my kidneys?" question — the acute dehydration-driven AKI risk versus the FLOW renoprotection data — see does Ozempic damage your kidneys?.